Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
19.1 (1y: -16%)
Market Cap 791.7 M P/E(ttm) 124.70
Enterprise Value 727.93 M P/B 3.00
LMNX- NAS (USA)
Luminex Corporation
  • Currently 1/5
Business Predictability Rank: 1-Star (On Watch)
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$19.10
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry		 vs
history
Cash to Debt 19.858
LMNX's Cash to Debt is ranked lower than
628930% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.63 vs. LMNX: 19.858 )
LMNX' s 10-Year Cash to Debt Range
Min: 11.48   Max: No Debt
Current: 19.86
Equity to Asset 0.483
LMNX's Equity to Asset is ranked lower than
699300% of the 143 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.56 vs. LMNX: 0.483 )
LMNX' s 10-Year Equity to Asset Range
Min: 0.38   Max: 0.94
Current: 0.48
0.38
0.94
Interest Coverage 114.7
LMNX's Interest Coverage is ranked lower than
877192% of the 114 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 73.90 vs. LMNX: 114.7 )
LMNX' s 10-Year Interest Coverage Range
Min: 6   Max: No Debt
Current: 114.7
F-Score: 7
Z-Score: 12.89
M-Score: -3.25
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry		 vs
history
Operating margin (%) 11.20
LMNX's Operating margin (%) is ranked lower than
892856% of the 112 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 13.00 vs. LMNX: 11.20 )
LMNX' s 10-Year Operating margin (%) Range
Min: -306.5   Max: 12.9
Current: 11.2
-306.5
12.9
Net-margin (%) 6.1
LMNX's Net-margin (%) is ranked lower than
980391% of the 102 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.20 vs. LMNX: 6.1 )
LMNX' s 10-Year Net-margin (%) Range
Min: -296.8   Max: 14.7
Current: 6.1
-296.8
14.7
ROE (%) 4.8
LMNX's ROE (%) is ranked lower than
990098% of the 101 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.30 vs. LMNX: 4.8 )
LMNX' s 10-Year ROE (%) Range
Min: -82.9   Max: 8.1
Current: 4.8
-82.9
8.1
ROA (%) 4.2
LMNX's ROA (%) is ranked lower than
980391% of the 102 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.30 vs. LMNX: 4.2 )
LMNX' s 10-Year ROA (%) Range
Min: -73   Max: 7.1
Current: 4.2
-73
7.1
ROC (Joel Greenblatt) (%) 30.90
LMNX's ROC (Joel Greenblatt) (%) is ranked lower than
900900% of the 111 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.40 vs. LMNX: 30.90 )
LMNX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -339.3   Max: 38.3
Current: 30.9
-339.3
38.3
Revenue Growth (%) 13.7
LMNX's Revenue Growth (%) is ranked lower than
1176469% of the 85 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.60 vs. LMNX: 13.7 )
LMNX' s 10-Year Revenue Growth (%) Range
Min: 8.3   Max: 32.8
Current: 13.7
8.3
32.8
EBITDA Growth (%) 23.7
LMNX's EBITDA Growth (%) is ranked lower than
1587300% of the 63 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.70 vs. LMNX: 23.7 )
LMNX' s 10-Year EBITDA Growth (%) Range
Min: -58.7   Max: 34.1
Current: 23.7
-58.7
34.1
EPS Growth (%) -8.6
LMNX's EPS Growth (%) is ranked lower than
1923075% of the 52 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 14.30 vs. LMNX: -8.6 )
LMNX' s 10-Year EPS Growth (%) Range
Min: -43   Max: 71.2
Current: -8.6
-43
71.2
ยป LMNX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

LMNX Guru Trades in Q2 2012

Steven Cohen 12,700 sh (New)
Paul Tudor Jones 24,000 sh (+77.78%)
RS Investment Management 457,960 sh (+59.55%)
Manning & Napier Advisors, Inc 492,174 sh (+0.39%)
Ron Baron 978,170 sh (+0.01%)
Chuck Royce 20,000 sh (unchged)
PRIMECAP Management Sold Out
Jim Simons 79,200 sh (-3.93%)
» More
Q3 2012

LMNX Guru Trades in Q3 2012

PRIMECAP Management 2,495,582 sh (New)
Manning & Napier Advisors, Inc 673,380 sh (+36.82%)
Chuck Royce 20,000 sh (unchged)
Jim Simons Sold Out
Ron Baron Sold Out
Steven Cohen 11,700 sh (-7.87%)
Paul Tudor Jones 17,700 sh (-26.25%)
RS Investment Management 149,657 sh (-67.32%)
» More
Q4 2012

LMNX Guru Trades in Q4 2012

Manning & Napier Advisors, Inc 919,960 sh (+36.62%)
PRIMECAP Management 2,543,292 sh (+1.91%)
Paul Tudor Jones 18,000 sh (+1.69%)
Chuck Royce 20,000 sh (unchged)
RS Investment Management Sold Out
Steven Cohen Sold Out
» More
Q1 2013

LMNX Guru Trades in Q1 2013

Jim Simons 54,340 sh (New)
Manning & Napier Advisors, Inc Sold Out
Paul Tudor Jones Sold Out
Chuck Royce Sold Out
PRIMECAP Management 2,490,480 sh (-2.08%)
» More
» Details

Insider Trades

Latest Guru Trades with LMNX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2012-09-30 Sold Out 0.15%$16.95 - $25.66 $ 18.96-2%0
PRIMECAP Management 2012-09-30 New Buy0.08%$16.95 - $25.66 $ 18.96-2%2495582
PRIMECAP Management 2012-06-30 Sold Out 0.09%$21.52 - $25.14 $ 18.96-19%0
Ron Baron 2011-09-30 Reduce -30%0.05%$18.5 - $24.62 $ 18.96-11%951610
Ron Baron 2010-09-30 Add 58.13%0.05%$14.34 - $16.74 $ 18.9622%1287212
Ron Baron 2010-06-30 New Buy0.09%$15.73 - $17.99 $ 18.9612%814000
PRIMECAP Management 2010-06-30 Add 20.56%0.01%$15.73 - $17.99 $ 18.9612%2108019
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/E(ttm) 124.70
LMNX's P/E(ttm) is ranked lower than
934579% of the 107 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.90 vs. LMNX: 124.70 )
LMNX' s 10-Year P/E(ttm) Range
Min: 27.36   Max: 603.33
Current: 124.7
27.36
603.33
P/B 3.00
LMNX's P/B is ranked lower than
657894% of the 152 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.50 vs. LMNX: 3.00 )
LMNX' s 10-Year P/B Range
Min: 2.32   Max: 12.9
Current: 3
2.32
12.9
P/S 3.80
LMNX's P/S is ranked lower than
628930% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.30 vs. LMNX: 3.80 )
LMNX' s 10-Year P/S Range
Min: 3.26   Max: 91.89
Current: 3.8
3.26
91.89
PFCF 35.60
LMNX's PFCF is ranked lower than
1063829% of the 94 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.70 vs. LMNX: 35.60 )
LMNX' s 10-Year PFCF Range
Min: 27.1   Max: 451.73
Current: 35.6
27.1
451.73
EV-to-EBIT 45.5
LMNX's EV-to-EBIT is ranked lower than
704225% of the 142 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.73 vs. LMNX: 45.5 )
LMNX' s 10-Year EV-to-EBIT Range
Min: 26.8   Max: 232.4
Current: 45.5
26.8
232.4
PEG 3.2
LMNX's PEG is ranked lower than
1694914% of the 59 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. LMNX: 3.2 )
LMNX' s 10-Year PEG Range
Min: 2.96   Max: 3.45
Current: 3.2
2.96
3.45
Shiller P/E 95
LMNX's Shiller P/E is ranked lower than
100% of the Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: vs. LMNX: 95 )
LMNX' s 10-Year Shiller P/E Range
Min: 73.14   Max: 309.4
Current: 95
73.14
309.4

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 41.2
LMNX's Price/Net Cash is ranked lower than
1999998% of the 50 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.90 vs. LMNX: 41.2 )
LMNX' s 10-Year Price/Net Cash Range
Min: 3.7   Max: 39.6
Current: 41.2
3.7
39.6
Price/Net Current Asset Value 19.8
LMNX's Price/Net Current Asset Value is ranked lower than
684931% of the 146 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 15.00 vs. LMNX: 19.8 )
LMNX' s 10-Year Price/Net Current Asset Value Range
Min: 17.5   Max: 96.5
Current: 19.8
17.5
96.5
Price/Tangible Book 5.5
LMNX's Price/Tangible Book is ranked lower than
704225% of the 142 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.60 vs. LMNX: 5.5 )
LMNX' s 10-Year Price/Tangible Book Range
Min: 2.6   Max: 11.9
Current: 5.5
2.6
11.9
Price/DCF (Projected) 2
LMNX's Price/DCF (Projected) is ranked lower than
1538460% of the 65 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.50 vs. LMNX: 2 )
LMNX' s 10-Year Price/DCF (Projected) Range
Min: 1.9   Max: 11.5
Current: 2
1.9
11.5
Price/Median PS Value 0.5
LMNX's Price/Median PS Value is ranked lower than
649350% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. LMNX: 0.5 )
LMNX' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 9
Current: 0.5
0.4
9
Price/Peter Lynch Fair Value 5
LMNX's Price/Peter Lynch Fair Value is ranked lower than
3124997% of the 32 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.70 vs. LMNX: 5 )
LMNX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.4   Max: 13.1
Current: 5
1.4
13.1
Price/Graham Number 4
LMNX's Price/Graham Number is ranked lower than
1041666% of the 96 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.20 vs. LMNX: 4 )
LMNX' s 10-Year Price/Graham Number Range
Min: 2.4   Max: 9.8
Current: 4
2.4
9.8
Earnings Yield (Greenblatt) 2.20
LMNX's Earnings Yield (Greenblatt) is ranked lower than
799999% of the 125 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.90 vs. LMNX: 2.20 )
LMNX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 3.7
Current: 2.2
0.4
3.7
Forward Rate of Return (Yacktman) 37.13
LMNX's Forward Rate of Return (Yacktman) is ranked lower than
1960782% of the 51 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 13.37 vs. LMNX: 37.13 )
LMNX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.1   Max: 37.7
Current: 37.13
-0.1
37.7

Business Description

Luminex Corporation was incorporated under the laws of the State of Texas in May 1995, and it began commercial production of its Luminex 100 System in 1999. It was reincorporated in the State of Delaware in July 2000. The Company develops, manufactures and sells proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. These industries depend on a broad range of tests, called bioassays, to perform diagnostic tests, discover and develop new drugs and identify genes. The Company's xMAP(r) technology, an open architecture, multiplexing technology, allows simultaneous analysis of up to 500 bioassays from a small sample volume, typically a single drop of fluid, by reading biological tests on the surface of microscopic polystyrene beads called microspheres. xMAP technology combines this miniaturized liquid array bioassay capability with small lasers, digital signal processors and proprietary software to create a system offering advantages in speed, precision, flexibility and cost. The Company's xMAP technology is currently being used within various segments of the life sciences industry which includes the fields of drug discovery and development, clinical diagnostics, genetic analysis, bio-defense, protein analysis and biomedical research. The Company business is currently organized into two reportable segments: the technology segment and the assay segment. The technology segment was initially built around strategic partnerships.As of December 31, 2011, it had approximately 66 strategic partners, 43 of which have developed reagent-based products utilizing technology. It also develops and manufactures the proprietary xMAP laboratory instrumentation and the proprietary xMAP microspheres and sells these products to its partners. The assay segment consists of Luminex Bioscience Group, or LBG, and Luminex Molecular Diagnostics, or LMD. This segment is mainly involved in the development and sale of assays utilizing xMAP technology on its installed base of systems. It is focused on generating recurring revenues from royalties on bioassay kits and testing services developed or performed by others that use its technology, as well as the sale of Luminex-developed assays, microspheres and other consumables. The Company's competition includes companies marketing conventional testing products based on established technologies such as ELISA, real-time PCR, mass spectrometry, sequencing, gels, biochips and flow-based technologies as well as companies developing their own advanced testing technologies. The Company's diagnostic market competitors include Abbott Laboratories, Beckman Coulter, Inc., Celera Corporation, Cepheid, Johnson & Johnson, Roche Diagnostics, Siemens Medical, and Hologic, Inc. among others. The Company's trademarks are Luminex(r), xMAP(r), xTAG(r), Luminex(r) 100(tm), Luminex(r) 200(tm), Luminex(r) XYP(tm), Luminex(r) SD(tm), Luminex HTSTM, FLEXMAP 3D(r), Mic
Company Website
SEC Reports
Industry: Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO
Traded in other countries:LMX.Germany
ยป More Articles for LMNX

Headlines

Articles On GuruFocus.com
BSX and ABMD Highlight Increased Insider Buying in the Medical Technology Sector May 14 2013 
Luminex Corp. (LMNX) CEO Patrick J Balthrop buys 7,000 Shares Mar 02 2010 
Luminex Corp. (LMNX) CEO Patrick J Balthrop buys 7,000 Shares Nov 16 2009 
PRIMECAP Management Buys Electronic Arts Inc., John Wiley & Sons Inc., Kellogg Company, Sells Data D Nov 14 2009 
Guru Stocks at 52-Week Low: MetroPCS Communications Inc, Leap Wireless International Inc, Glacier Ba Nov 07 2009 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial